Form 4: Tonix Pharmaceuticals Director James Treco Acquires Stock Options
SEC Form 4 Filing
Director James Treco acquired stock options in Tonix Pharmaceuticals, according to a Form 4 filing.
Summary
- James Treco, a director of Tonix Pharmaceuticals Holding Corp., acquired stock options on May 23, 2024.
- The options are for 104,621 shares of common stock at an exercise price of $0.1745.
- The options vest on the earlier of one year from the grant date or the company's 2025 Annual Meeting of Stockholders and expire on May 23, 2034.
- Following the transaction, Treco directly owns 104,621 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director acquiring stock options suggests confidence, but it's a routine transaction.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting of the options is tied to the company's 2025 Annual Meeting of Stockholders, suggesting a focus on long-term performance.
Industry Context
Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's stock.
Stakeholder Impact
- The acquisition of stock options by a director could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/23/2024 | Date of the stock option grant. |
| 05/23/2025 | Expiration date of the vesting period, one year after the grant date. |
| 05/23/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.